AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial

Key TakeawaysA breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial.The trial included over 700 patients with inoperable or metastatic breast cancer.The company said it will present the new data to regulators who are weighing approval of the drug. Its shares fell Monday morning. British drugmaker AstraZeneca (AZN) said Monday that a Phase 3 trial of a developmental drug failed to achieve "sta ...